ANI PHARMACEUTICALS, INC Revenues
ANI PHARMACEUTICALS, INC (ANIP) reported Revenues of $49.77 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Income Statement
us-gaap:Revenues · last filed 2020-05-07
- ANI PHARMACEUTICALS, INC revenues for the quarter ending 2020-03-31 was $49.77M, a 5.89% decline year-over-year.
- ANI PHARMACEUTICALS, INC revenues for the quarter ending 2019-12-31 was $47.97M, a 16.03% decline year-over-year.
- ANI PHARMACEUTICALS, INC revenues for the quarter ending 2019-09-30 was $51.34M, a 1.25% increase year-over-year.
- ANI PHARMACEUTICALS, INC revenues for the quarter ending 2019-06-30 was $54.36M, a 15.00% increase year-over-year.
- ANI PHARMACEUTICALS, INC revenues for fiscal 2019 was $206.55M, a 2.47% increase from fiscal 2018.
- ANI PHARMACEUTICALS, INC revenues for fiscal 2018 was $201.58M, a 13.99% increase from fiscal 2017.
- ANI PHARMACEUTICALS, INC revenues for fiscal 2017 was $176.84M, a 37.49% increase from fiscal 2016.
- ANI PHARMACEUTICALS, INC revenues for fiscal 2016 was $128.62M, a 68.53% increase from fiscal 2015.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 6 month as first filed | Revenues 9 month | Revenues 9 month as first filed | Revenues 12 month | Revenues 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | $49.77M 10-Q · filed 2020-05-07 | $97.74M derived: sum of 2 quarters · filed 2020-05-07 | $149.08M derived: sum of 3 quarters · filed 2020-05-07 | $203.43M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2019-12-31 | $47.97M 10-K · filed 2020-02-27 | $99.30M derived: sum of 2 quarters · filed 2020-02-27 | $153.66M derived: sum of 3 quarters · filed 2020-02-27 | $206.55M 10-K · filed 2020-02-27 | ||||
| 2019-09-30 | $51.34M 10-K · filed 2020-02-27 | $105.69M derived: sum of 2 quarters · filed 2020-02-27 | $158.58M 10-Q · filed 2019-11-06 | $215.70M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2019-06-30 | $54.36M 10-K · filed 2020-02-27 | $107.24M 10-Q · filed 2019-08-07 | $164.37M derived: sum of 3 quarters · filed 2020-05-07 | $215.07M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2019-03-31 | $52.89M 10-Q · filed 2020-05-07 | $110.01M derived: sum of 2 quarters · filed 2020-05-07 | $160.71M derived: sum of 3 quarters · filed 2020-05-07 | $207.98M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $57.12M 10-K · filed 2020-02-27 | $107.83M derived: sum of 2 quarters · filed 2020-02-27 | $155.09M derived: sum of 3 quarters · filed 2020-02-27 | $201.58M 10-K · filed 2020-02-27 | ||||
| 2018-09-30 | $50.70M 10-K · filed 2020-02-27 | $97.97M derived: sum of 2 quarters · filed 2020-02-27 | $144.45M 10-Q · filed 2019-11-06 | $191.74M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $47.27M 10-K · filed 2020-02-27 | $93.75M 10-Q · filed 2019-08-07 | $141.04M derived: sum of 3 quarters · filed 2020-02-27 | $189.20M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $46.48M 10-K · filed 2020-02-27 | $93.77M derived: sum of 2 quarters · filed 2020-02-27 | $141.93M derived: sum of 3 quarters · filed 2020-02-27 | $186.70M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $47.29M 10-K · filed 2019-02-27 | $95.45M derived: sum of 2 quarters · filed 2019-02-27 | $140.21M derived: sum of 3 quarters · filed 2019-02-27 | $176.84M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $48.16M 10-K · filed 2019-02-27 | $92.93M derived: sum of 2 quarters · filed 2019-02-27 | $129.56M 10-Q · filed 2018-11-06 | $167.76M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | $44.76M 10-K · filed 2019-02-27 | $81.39M 10-Q · filed 2018-08-07 | $119.60M derived: sum of 3 quarters · filed 2019-02-27 | $158.12M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | $36.63M 10-K · filed 2019-02-27 | $74.83M derived: sum of 2 quarters · filed 2019-02-27 | $113.36M derived: sum of 3 quarters · filed 2019-02-27 | $144.69M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $38.20M 10-K · filed 2018-02-27 | $76.73M derived: sum of 2 quarters · filed 2018-02-27 | $108.07M derived: sum of 3 quarters · filed 2018-02-27 | $128.62M 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | $38.52M 10-K · filed 2018-02-27 | $69.86M derived: sum of 2 quarters · filed 2018-02-27 | $90.42M 10-Q · filed 2017-11-02 | $108.45M derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-06-30 | $31.34M 10-K · filed 2018-02-27 | $51.89M 10-Q · filed 2017-08-03 | $69.93M derived: sum of 3 quarters · filed 2018-02-27 | $89.90M derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2016-03-31 | $20.55M 10-K · filed 2018-02-27 | $38.59M derived: sum of 2 quarters · filed 2018-02-27 | $58.56M derived: sum of 3 quarters · filed 2018-02-27 | $78.08M derived: sum of 4 quarters · filed 2018-02-27 | ||||
| 2015-12-31 | $18.04M 10-K · filed 2017-03-02 | $38.01M derived: sum of 2 quarters · filed 2017-03-02 | $57.52M derived: sum of 3 quarters · filed 2017-03-02 | $76.32M 10-K · filed 2018-02-27 | ||||
| 2015-09-30 | $19.97M 10-K · filed 2017-03-02 | $39.49M derived: sum of 2 quarters · filed 2017-03-02 | $58.29M 10-Q · filed 2016-11-03 | $79.32M derived: sum of 4 quarters · filed 2017-03-02 | ||||
| 2015-06-30 | $19.52M 10-K · filed 2017-03-02 | $38.31M 10-Q · filed 2016-08-04 | $59.35M derived: sum of 3 quarters · filed 2017-03-02 | $76.74M derived: sum of 4 quarters · filed 2017-03-02 | ||||
| 2015-03-31 | $18.80M 10-K · filed 2017-03-02 | $39.84M derived: sum of 2 quarters · filed 2017-03-02 | $57.22M derived: sum of 3 quarters · filed 2017-03-02 | $63.87M derived: sum of 4 quarters · filed 2017-03-02 | ||||
| 2014-12-31 | $21.04M 10-K · filed 2016-02-23 | $38.42M derived: sum of 2 quarters · filed 2016-02-23 | $45.07M derived: sum of 3 quarters · filed 2016-02-23 | $55.97M 10-K · filed 2017-03-02 | ||||
| 2014-09-30 | $17.39M 10-K · filed 2016-02-23 | $24.03M derived: sum of 2 quarters · filed 2016-02-23 | $34.93M 10-Q · filed 2015-11-03 | $45.47M derived: sum of 4 quarters · filed 2016-02-23 | ||||
| 2014-06-30 | $6.65M 10-K · filed 2016-02-23 | $17.55M 10-Q · filed 2015-08-04 | $28.08M derived: sum of 3 quarters · filed 2016-02-23 | $35.91M derived: sum of 4 quarters · filed 2016-02-23 | ||||
| 2014-03-31 | $10.90M 10-K · filed 2016-02-23 | $21.43M derived: sum of 2 quarters · filed 2016-02-23 | $29.27M derived: sum of 3 quarters · filed 2016-02-23 | $35.42M derived: sum of 4 quarters · filed 2016-02-23 | ||||
| 2013-12-31 | $10.53M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $18.37M derived: sum of 2 quarters · filed 2016-02-23 | $24.52M derived: sum of 3 quarters · filed 2016-02-23 | $30.08M 10-K · filed 2016-02-23 | ||||
| 2013-09-30 | $7.84M 10-Q · filed 2014-11-10 | $7.84M 10-Q · filed 2013-11-07 | $13.99M derived: sum of 2 quarters · filed 2014-11-10 | $19.55M 10-Q · filed 2014-11-10 | $19.55M 10-Q · filed 2013-11-07 | $21.52M derived: sum of 4 quarters · filed 2014-11-10 | ||
| 2013-06-30 | $6.15M 10-Q · filed 2014-08-07 | $6.15M 10-Q · filed 2013-08-09 | $11.71M 10-Q · filed 2014-08-07 | $11.71M 10-Q · filed 2013-08-09 | $13.68M derived: sum of 3 quarters · filed 2014-08-07 | $18.72M derived: sum of 4 quarters · filed 2014-08-07 | ||
| 2013-03-31 | $5.56M 10-Q · filed 2014-05-12 | $145.04K 10-Q · filed 2013-05-10 | $7.53M derived: sum of 2 quarters · filed 2014-05-12 | $12.57M derived: sum of 3 quarters · filed 2014-05-12 | $17.75M derived: sum of 4 quarters · filed 2014-05-12 | |||
| 2012-12-31 | $1.97M 10-K · filed 2013-02-28 | $7.00M derived: sum of 2 quarters · filed 2013-11-07 | $12.19M derived: sum of 3 quarters · filed 2013-11-07 | $20.37M 10-K · filed 2014-02-28 | $2.30M 10-K · filed 2013-02-28 | |||
| 2012-09-30 | $5.04M 10-Q · filed 2013-11-07 | $110.38K 10-Q · filed 2012-11-08 | $10.22M derived: sum of 2 quarters · filed 2013-11-07 | $15.05M 10-Q · filed 2013-11-07 | $333.16K 10-Q · filed 2012-11-08 | $10.45M derived: sum of 4 quarters · filed 2013-11-07 | ||
| 2012-06-30 | $5.19M 10-Q · filed 2013-08-09 | $108.78K 10-Q · filed 2012-08-01 | $10.01M 10-Q · filed 2013-08-09 | $222.78K 10-Q · filed 2012-08-01 | $5.42M derived: sum of 3 quarters · filed 2013-08-09 | $5.60M derived: sum of 4 quarters · filed 2013-08-09 | ||
| 2012-03-31 | $114.00K 10-Q · filed 2013-05-10 | $228.37K derived: sum of 2 quarters · filed 2013-05-10 | $411.16K derived: sum of 3 quarters · filed 2013-05-10 | $492.16K derived: sum of 4 quarters · filed 2013-05-10 | ||||
| 2011-12-31 | $114.37K 10-K · filed 2013-02-28 | $297.16K derived: sum of 2 quarters · filed 2013-02-28 | $378.16K derived: sum of 3 quarters · filed 2013-02-28 | $435.16K 10-K · filed 2013-02-28 | ||||
| 2011-09-30 | $182.78K 10-K · filed 2013-02-28 | $263.79K derived: sum of 2 quarters · filed 2013-02-28 | $320.79K 10-Q · filed 2012-11-08 | $463.82K derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-06-30 | $81.00K 10-K · filed 2013-02-28 | $138.00K 10-Q · filed 2012-08-01 | $281.04K derived: sum of 3 quarters · filed 2013-02-28 | $332.37K derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2011-03-31 | $57.00K 10-K · filed 2013-02-28 | $200.03K derived: sum of 2 quarters · filed 2013-02-28 | $251.36K derived: sum of 3 quarters · filed 2013-02-28 | $251.36K derived: sum of 4 quarters · filed 2013-02-28 | ||||
| 2010-12-31 | $143.03K 8-K · filed 2013-01-28 | $194.36K derived: sum of 2 quarters · filed 2013-01-28 | $194.36K derived: sum of 3 quarters · filed 2013-01-28 | $2.47M 10-K · filed 2013-02-28 | ||||
| 2010-09-30 | $51.33K 8-K · filed 2013-01-28 | $51.33K derived: sum of 2 quarters · filed 2013-01-28 | $2.33M 10-Q · filed 2011-11-09 | |||||
| 2010-06-30 | $0.00 8-K · filed 2013-01-28 | $2.28M 10-Q · filed 2011-08-05 | ||||||
| 2010-03-31 | $2.28M 8-K · filed 2013-01-28 | |||||||
| 2009-12-31 | $1.26M 8-K · filed 2013-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |